11 completed. 11 Phase 3, 3 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 11 | Completed 11 |
| Phase 2 | 3 | Completed 3 |
Follow Animal Diseases: new trials by email Literature Review of Animal Diseases trials Research Report on Animal Diseases
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study on Immunogenicity, Reactogenicity and Safety of the VACΔ6 Vaccine in Volunteers Aged 18-60 Years VAC∆6 vaccine (10⁷ PFU), VAC∆6 vaccine (10⁶ PFU), Live Smallpox Vaccine - Smallpox, Monkeypox | Phase 2 / Phase 3 | Completed | Federal Budgetary Research Institution State Research Center of Virology and Biotechnology "Vector" | 334 | 2021-10-01 | 2023-05-06 |
| A Study to Evaluate the Efficacy, Immunogenicity and Safety of an EV71 Vaccine in Healthy Infants and Children EV71 vaccine, Placebo - Enterovirus Infections | Phase 3 | Completed | Enimmune Corporation | 3982 | 2018-06-27 | 2026-09-11 |
| A Safety and Immunogenicity Study of IVACFLU-A/H5N1 IVACFLU-A/H5N1 vaccine, Placebo - Avian Influenza | Phase 2 / Phase 3 | Completed | Institute of Vaccines and Medical Biologicals, Vietnam | 930 | 2017-03-07 | 2019-05-21 |
| JYNNEOS Smallpox Vaccine in Adult Healthcare Personnel at Risk for Mpox in the Democratic Republic of the Congo JYNNEOS (Liquid Formulation), JYNNEOS (Lyophilized Formulation) - Monkeypox Virus Infection | Phase 3 | Completed | Centers for Disease Control and Prevention | 1600 | 2017-02-23 | 2026-04-23 |
| A Study to Evaluate Safety, Immunogenicity, and Lot-to-Lot Consistency of H5N1 Subunit Influenza Virus Vaccine in Healthy Adult Subjects ≥18 Years of Age aH5N1c, Placebo - Avian Influenza | Phase 3 | Completed | Seqirus | 3196 | 2016-07-11 | 2024-12-06 |
| Safety and Immunogenicity of Two Doses of aH5N1 Vaccine in Adult and Elderly Subjects With and Without Underlying Medical Conditions Novartis Investigational H5N1 vaccine, Novartis Seasonal Influenza Vaccine - Influenza, Human | Phase 3 | Completed | Seqirus | 540 | 2014-04-01 | 2016-11-04 |
| Safety and Immunogenicity of Two Doses of aH5N1 Vaccine in Adult and Elderly Subjects With and Without Immunosuppressive Conditions *aH5N1:Monovalent H5N1 Influenza Vaccine Novartis Investigational H5N1 vaccine, Novartis Seasonal Influenza Vaccine - Influenza, Human, Flu, Human | Phase 3 | Completed | Seqirus | 539 | 2014-04-01 | 2016-05-09 |
| Phase III Study to Evaluate the Immunogenicity and Safety of MG1109 in Healthy Adult Volunteers MG1109, Placebo - Influenza | Phase 3 | Completed | Green Cross Corporation | 420 | 2013-08-01 | 2015-07-03 |
| Efficacy and Safety Study of Adalimumab in Treatment of Hidradenitis Suppurativa adalimumab, placebo - Hidradenitis Suppurativa (HS) | Phase 3 | Completed | AbbVie (prior sponsor, Abbott) | 307 | 2011-11-01 | 2021-07-07 |
| Efficacy and Safety Study of Adalimumab in the Treatment of Hidradenitis Suppurativa adalimumab, placebo - Hidradenitis Suppurativa (HS) | Phase 3 | Completed | AbbVie (prior sponsor, Abbott) | 326 | 2011-11-01 | 2021-07-12 |
| H5N1 Vaccine Study in Japanese Adults H5N1 (pre-)pandemic influenza vaccine (whole virion, Vero Cell derived, inactivated) - H5N1 Influenza | Phase 2 / Phase 3 | Completed | Alachua Government Services, Inc. | 340 | 2011-06-01 | 2015-10-09 |
Influenza in Birds (6) · Influenza, Human (4) · Acne Vulgaris (2) · Furunculosis (2) · Hidradenitis Suppurativa (2) · Mpox, Monkeypox (2) · Psoriasis (2) · Cowpox (1) · Enterovirus Infections (1) · Foot-and-Mouth Disease (1) · Hand, Foot and Mouth Disease (1) · Smallpox (1) · Vaccinia (1)
Infections (11) · Virus Diseases (9) · RNA Virus Infections (7) · Bird Diseases (6) · Orthomyxoviridae Infections (6) · Respiratory Tract Diseases (4) · Respiratory Tract Infections (4) · Acneiform Eruptions (2) · Bacterial Infections (2) · Bacterial Infections and Mycoses (2) · DNA Virus Infections (2) · Fish Diseases (2) · Gram-Positive Bacterial Infections (2) · Hidradenitis (2)
Adalimumab (2) · smallpox and monkeypox vaccine modified vaccinia ankara-bavarian nordic (1)
Seqirus (3) · AbbVie (prior sponsor, Abbott) (2) · Alachua Government Services, Inc. (1) · Centers for Disease Control and Prevention (1) · Enimmune Corporation (1) · Federal Budgetary Research Institution State Research Center of Virology and Biotechnology "Vector" (1) · Green Cross Corporation (1) · Institute of Vaccines and Medical Biologicals, Vietnam (1)
Germany (2) · Vietnam (2) · Australia (1) · Democratic Republic of the Congo (1) · Italy (1) · Japan (1) · Russia (1) · South Korea (1) · Taiwan (1) · United States (1)
Alexander Geisberger, MD (1) · Chin-Fen Yang (1) · David Williams, MD (1) · Faisal Minhaj, Pharm.D., MPH, DABAT (1) · Irina V Krasil'nikova, PhD (1) · Kinkodi Didine Kaba, MD, PhD (1) · Martin Okun, MD (1) · Tran N Duong, MD, PhD (1) · Vladimir I. Kuzubov, PhD (1) · Woo Joo Kim, MD, Ph.D (1)
PMID 27518661, PMID 29380251, PMID 39141589, PMID 30445121, PMID 31812464, PMID 35455245, PMID 36263798, PMID 41680199, PMID 41819114, PMID 41819117